Transforming growth factor J3 type II receptor (TGFpRII) mutation in gastric lymphoma without mutator phenotype
Kazuhiko Yasuml
The First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorRong-Jun Guo
The First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorHiroyuki Hanai
The First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorHajime Arai
The First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorEizo Kaneko
The First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorHiroyuki Konno
The Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorSelichi Takenoshita
Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, Maryland, United States of America
Search for more papers by this authorKoichi Hagiwara
Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, Maryland, United States of America
Search for more papers by this authorCorresponding Author
Haruhiko Sugimura
The First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
The First Department of Pathology, Hamamatsu University School of Medicine, 3600 Handa cho, Hamamatsu 431–31, Japan. Email: <[email protected]>Search for more papers by this authorKazuhiko Yasuml
The First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorRong-Jun Guo
The First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorHiroyuki Hanai
The First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorHajime Arai
The First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorEizo Kaneko
The First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorHiroyuki Konno
The Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
Search for more papers by this authorSelichi Takenoshita
Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, Maryland, United States of America
Search for more papers by this authorKoichi Hagiwara
Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, Maryland, United States of America
Search for more papers by this authorCorresponding Author
Haruhiko Sugimura
The First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
The First Department of Pathology, Hamamatsu University School of Medicine, 3600 Handa cho, Hamamatsu 431–31, Japan. Email: <[email protected]>Search for more papers by this authorAbstract
A new mutation in the serine-threonine klnase domain of the transforming growth factor β type II receptor (TGFpRII) was found in a case of diffuse, B cell non-Hodgkin's lymphoma of the stomach. A mfssense mutation (ACA to GCA, Thr to Ala) was detected In exon 5, and a wild type allele was also present. This Is the first naturally occurring mutation in the klnase domain of this gene identified in human primary lymphoma. The replication error at three loci was negative, and the poly A tract of exon 3, which is frequently a target of mismatch repair genes, was intact. Malignant lymphoma of B cell origin in the stomach Is an addition to an expanding catalogue of tumors with TGFβRII alterations, and the biological sequelae of the change in the functional domain and the clinical characteristics of the patient in this study are intriguing.
REFERENCES
- 1 Igarashi H, Sugimura H, Maruyamaet Al. Alteration of immunoreactivity by hydrated autoclaving, microwave treatment, and simple heating of paraffin-embedded tissue sections. APMIS 1994; 102: 295–307.
- 2 Takenoshita S, Hagiwara K, Nagashima M et al. The genomic structure of the gene encoding the human transforming growth factor beta type II receptor (TGF-beta Rll). Genomics 1996; 36: 341–344.
- 3 Dobashi Y, Sugimura H, Sakamoto A et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn. Mol Pathol.. 1994; 3: 9–14.
- 4 Shinmura K, Sugimura H, Naito Y et al. Frequent co-occurrence of mutator phenotype in synchronous, independent multiple cancers of the stomach. Carcinogenesis 1995; 16: 2989–2993.
- 5 Lu SL, Zhang WC, Akiyama Y et al. Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res. 1996; 56: 4595–4598.
- 6 Nakamura S, Akazawa K, Kinukawa N et al. Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma (comments). Hum. Pathol. 1996; 27: 225–233.
- 7 Miyazono K. TGF-beta receptors and signal transduction. Int. J. Hematol. 1997; 65: 97–104.
- 8 Lu SL, Akiyama Y, Nagasaki H et al. Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem. Biophys. Res. Commun. 1995; 216: 452–457.
- 9 Takenoshita S, Tani M, Nagashima M et al. Mutation analysis of coding sequences of the entire transforming growth factor beta type Il receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene 1997; 14: 1255–1258.
- 10 Tani M, Takenoshita S, Kohno T et al. Infrequent mutations of the transforming growth factor beta-type II receptor gene at chromosome 3p22 in human lung cancers with chromosome 3p deletions. Carcinogenesis 1997; 18: 1119–1121.
- 11 Garrigue-Antar L, Munoz-Antonia T, Antonia SJ et al. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res. 1995; 55: 3982–3987.
- 12 Kadin ME, Cavaille-Coll MW, Gertz R et al. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc. NatlAcad. Sci. USA 1994; 91: 6002–6006.
- 13 Chang J, Park K, Bang Y-J et al. Expression of transforming growth factor p type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res. 1997; 57: 2856–2859.
- 14 Lazzerschi D, Ranieri A, Mincione G et al. Human malignant thyroid tumors displayed reduced levels of transforming growth factor β receptor type II messenger RNA and protein. Cancer Res. 1997; 57: 2071–2076.
- 15 Munoz-Antonia T, Li X, Reiss M et al. A mutation in the transforming growth factor type II receptor gene promoter associated with loss of gene expression. Cancer Res. 1996; 56: 4831–4835.
- 16 Okamoto A, Jiang W, Kim SJ et al. Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line. Proc. NaO. Acad. Sci. USA 1994; 91: 11576–11580.
- 17 Gamberi B, Gaidano G, Parsa N et al. Microsatellite instability is rare in B-cell non-Hodgkin's lymphomas. Blood 1997; 89: 975–979.
Citing Literature
